Achilles Therapeutics (ACHL) Scheduled to Post Quarterly Earnings on Tuesday

Achilles Therapeutics (NASDAQ:ACHLGet Free Report) is set to issue its quarterly earnings data on Tuesday, April 2nd.

Achilles Therapeutics Stock Up 5.0 %

NASDAQ:ACHL opened at $1.25 on Monday. The company has a market capitalization of $50.98 million, a price-to-earnings ratio of -0.66 and a beta of 1.10. Achilles Therapeutics has a one year low of $0.74 and a one year high of $1.76. The stock has a 50-day simple moving average of $1.14 and a 200 day simple moving average of $0.96. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.55 and a current ratio of 8.55.

Hedge Funds Weigh In On Achilles Therapeutics

A number of large investors have recently bought and sold shares of ACHL. Virtu Financial LLC bought a new position in Achilles Therapeutics in the fourth quarter worth about $28,000. Bank of America Corp DE lifted its holdings in Achilles Therapeutics by 130.8% in the first quarter. Bank of America Corp DE now owns 10,450 shares of the company’s stock worth $31,000 after acquiring an additional 5,922 shares during the last quarter. Balyasny Asset Management LLC bought a new position in Achilles Therapeutics in the third quarter worth about $39,000. Jane Street Group LLC bought a new position in Achilles Therapeutics in the fourth quarter worth about $41,000. Finally, Sei Investments Co. bought a new position in Achilles Therapeutics in the second quarter worth about $59,000. Institutional investors own 56.38% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Bank of America reiterated an “underperform” rating on shares of Achilles Therapeutics in a research note on Thursday, December 14th.

Check Out Our Latest Analysis on Achilles Therapeutics

Achilles Therapeutics Company Profile

(Get Free Report)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

See Also

Earnings History for Achilles Therapeutics (NASDAQ:ACHL)

Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.